Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Omega-3 fatty acids may slow down early Alzheimer’s in some cases

10.10.2006
Omega-3 fatty acid supplements may slow cognitive decline in some patients with very mild Alzheimer’s disease, according to new findings from Karolinska Institutet (KI) in Sweden.

However, the positive affect of Omega-3 do not appear in cases with more advanced Alzheimer’s. This is the first clinical trial ever made in the field and the result is published in the October issue of Archives of Neurology, one of the JAMA/Archives journals.

Alzheimer’s disease is a severely debilitating condition that affects thinking, learning and memory, beginning with declines in episodic memory. Medications are available to treat the symptoms, but these drugs do not affect the underlying cause and progression of the disease. Several studies have shown that eating fish, which is high in omega-3 fatty acids, may protect against Alzheimer’s disease, leading researchers to question whether supplements could have similar effects.

Dr Yvonne Freund-Levi and colleagues at KI in Stockholm and Uppsala University in Uppsala, Sweden, compared the effects of supplements containing two omega-3 fatty acids with placebo in 204 patients with Alzheimer’s disease, by which 174 completed the entire study. For six months, 89 patients (51 women and 38 men) took 1.7 grams of docosahexaenoic acid (DHA) and .6 grams of eicosapentaenoic acid (EPA), while 85 patients (39 women and 46 men) took placebo. For an additional six months, both groups took the omega-3 fatty acids. Patients had physical examinations, which included blood tests and blood pressure measurement, and took cognitive tests at the beginning of the study and at the six- and 12-month marks.

After six months, there was no difference in the rate of cognitive decline between the two groups. However, among a subgroup of 32 patients with very mild cognitive impairment at the beginning of the study, those who took the fatty acids experienced less decline in six months compared with those who took placebo. Among those who took placebo during the first six months, decline decreased during the second six months, when they also began taking the omega-3 supplements. The supplements appeared safe and well-tolerated, with no change in blood pressure or blood test results other than a higher ratio of fatty acids in the blood.

“These findings cannot serve as a basis for general recommendations for treatment of Alzheimer’s disease with dietary DHA-rich fish oil preparations”, says professor Jan Palmblad. “Studies in larger cohorts with mild cognitive impairment, including those at risk for Alzheimer’s disease, are needed to further explore the possibility that omega-3 fatty acids might be beneficial in halting initial progression of the disease.”

Publication: Omega-3 fatty acid treatment of 174 patients with mild to moderate Alzheimer’s disease (OmegAD): a randomized double-blind trial, Yvonne Freund Levi, Maria Eriksdotter-Jönhagen, Tommy Cederholm, Hans Basun, Gerd Faxén Irving, Anita Garlind, Inger Vedin, Bengt Vessby, Lars-Olof Wahlund, Jan Palmblad, Archives of Neurology, October 2006, ref. 2006; 63:1402-1408.

For further information, please contact:

Professor Tommy Cederholm, Department of Public Care and Caring Sciences/Clinical Nutrition and Metabolism, Uppsala University
Phone: +46-70-2733192
Email: Tommy.Cederholm@pubcare.uu.se
Professor Lars-Olof Wahlund, Department of Neurobiology, Caring Sciences and Society, Huddinge, KI.
Phone +46-70-7892045
E-mail: Lars-Olof.Wahlund@ki.se
Professor Jan Palmblad, Deparment of Medicine, Huddinge, KI
Phone: +46-8-585 826 93
Email: Jan.Palmblad@ki.se
Dr Yvonne Freund-Levi, Department of Neurobiology, Caring Sciences and Society, Huddinge, KI.
Phone +46-70-7892045
E-mail: Yvonne.Freund-Levi@ki.se
KI Press Officer:
Katarina Sternudd
Phone: +46-8-524 838 95
Email: katarina.sternudd@ki.se

Katarina Sternudd | alfa
Further information:
http://ki.se

More articles from Health and Medicine:

nachricht Study tracks inner workings of the brain with new biosensor
16.08.2018 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht Foods of the future
15.08.2018 | Georg-August-Universität Göttingen

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Color effects from transparent 3D-printed nanostructures

New design tool automatically creates nanostructure 3D-print templates for user-given colors
Scientists present work at prestigious SIGGRAPH conference

Most of the objects we see are colored by pigments, but using pigments has disadvantages: such colors can fade, industrial pigments are often toxic, and...

Im Focus: Unraveling the nature of 'whistlers' from space in the lab

A new study sheds light on how ultralow frequency radio waves and plasmas interact

Scientists at the University of California, Los Angeles present new research on a curious cosmic phenomenon known as "whistlers" -- very low frequency packets...

Im Focus: New interactive machine learning tool makes car designs more aerodynamic

Scientists develop first tool to use machine learning methods to compute flow around interactively designable 3D objects. Tool will be presented at this year’s prestigious SIGGRAPH conference.

When engineers or designers want to test the aerodynamic properties of the newly designed shape of a car, airplane, or other object, they would normally model...

Im Focus: Robots as 'pump attendants': TU Graz develops robot-controlled rapid charging system for e-vehicles

Researchers from TU Graz and their industry partners have unveiled a world first: the prototype of a robot-controlled, high-speed combined charging system (CCS) for electric vehicles that enables series charging of cars in various parking positions.

Global demand for electric vehicles is forecast to rise sharply: by 2025, the number of new vehicle registrations is expected to reach 25 million per year....

Im Focus: The “TRiC” to folding actin

Proteins must be folded correctly to fulfill their molecular functions in cells. Molecular assistants called chaperones help proteins exploit their inbuilt folding potential and reach the correct three-dimensional structure. Researchers at the Max Planck Institute of Biochemistry (MPIB) have demonstrated that actin, the most abundant protein in higher developed cells, does not have the inbuilt potential to fold and instead requires special assistance to fold into its active state. The chaperone TRiC uses a previously undescribed mechanism to perform actin folding. The study was recently published in the journal Cell.

Actin is the most abundant protein in highly developed cells and has diverse functions in processes like cell stabilization, cell division and muscle...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

LaserForum 2018 deals with 3D production of components

17.08.2018 | Event News

Within reach of the Universe

08.08.2018 | Event News

A journey through the history of microscopy – new exhibition opens at the MDC

27.07.2018 | Event News

 
Latest News

Smallest transistor worldwide switches current with a single atom in solid electrolyte

17.08.2018 | Physics and Astronomy

Robots as Tools and Partners in Rehabilitation

17.08.2018 | Information Technology

Climate Impact Research in Hannover: Small Plants against Large Waves

17.08.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>